B

Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML

Watchlist Manager
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Watchlist
Price: 5.8 PLN 1.67% Market Closed
Market Cap: 378.5m PLN

Relative Value

There is not enough data to reliably calculate the relative value of BML.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BML Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
7.6
Median 5Y
7.6
Industry
7.9
vs History
vs Industry
Median 3Y
53.8
Median 5Y
53.8
Industry
23.7
vs History
vs Industry
Median 3Y
157.8
Median 5Y
157.8
Industry
22
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-11.9
Industry
24.3
vs History
vs Industry
Median 3Y
3.8
Median 5Y
3.8
Industry
3.3
vs History
vs Industry
Median 3Y
7.3
Median 5Y
7.3
Industry
8.2
vs History
vs Industry
Median 3Y
12.8
Median 5Y
12.8
Industry
10.2
vs History
vs Industry
Median 3Y
21.7
Median 5Y
21.7
Industry
6.1
vs History
vs Industry
Median 3Y
33.1
Median 5Y
33.1
Industry
6.5
vs History
vs Industry
Median 3Y
151.4
Median 5Y
151.4
Industry
7.9
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-9.2
Industry
6.3
vs History
vs Industry
Median 3Y
3
Median 5Y
3
Industry
5.7

Multiples Across Competitors

BML Competitors Multiples
Biomed Lublin Wytwornia Surowic i Szczepionek SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
407.5m PLN 7.6 53.8 21.7 33.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 686 905 -160 108.9 -194 423.2 -192 204.6
US
Abbvie Inc
NYSE:ABBV
408.8B USD 6.9 174.1 16.8 23.8
US
Amgen Inc
NASDAQ:AMGN
178.1B USD 5 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
154.6B USD 5.3 19.1 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.4B USD 9.9 31.7 23.3 24.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 091.3 -533.6 -581.1 -565.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82B USD 5.8 17.9 17.1 19.4
AU
CSL Ltd
ASX:CSL
84B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.6B USD 16.4 1 208.5 163 197.6
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.3 33.6 58 59.6
P/E Multiple
Earnings Growth PEG
PL
B
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Average P/E: 175.9
53.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 108.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
174.1
89%
2
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 208.5
N/A N/A
NL
argenx SE
XBRU:ARGX
33.6
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
B
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Average EV/EBITDA: 38.2
21.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 423.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.8
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163
N/A N/A
NL
argenx SE
XBRU:ARGX
58
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
PL
B
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Average EV/EBIT: 45
33.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 204.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.8
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.6
N/A N/A
NL
argenx SE
XBRU:ARGX
59.6
N/A N/A